ZA984571B - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases - Google Patents
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinasesInfo
- Publication number
- ZA984571B ZA984571B ZA984571A ZA984571A ZA984571B ZA 984571 B ZA984571 B ZA 984571B ZA 984571 A ZA984571 A ZA 984571A ZA 984571 A ZA984571 A ZA 984571A ZA 984571 B ZA984571 B ZA 984571B
- Authority
- ZA
- South Africa
- Prior art keywords
- p561lck
- quinoline
- growth factor
- derived growth
- tyrosine kinases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86445597A | 1997-05-28 | 1997-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA984571B true ZA984571B (en) | 1999-01-21 |
Family
ID=25343315
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA984572A ZA984572B (en) | 1997-05-28 | 1998-05-28 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth facto and/or p56ick tyrosine kinases |
ZA984571A ZA984571B (en) | 1997-05-28 | 1998-05-28 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases |
ZA984573A ZA984573B (en) | 1997-05-28 | 1998-05-28 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA984572A ZA984572B (en) | 1997-05-28 | 1998-05-28 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth facto and/or p56ick tyrosine kinases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA984573A ZA984573B (en) | 1997-05-28 | 1998-05-28 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR100480360B1 (en) |
CN (1) | CN101293869A (en) |
UA (2) | UA66361C2 (en) |
ZA (3) | ZA984572B (en) |
-
1998
- 1998-05-28 UA UA99127076A patent/UA66361C2/en unknown
- 1998-05-28 ZA ZA984572A patent/ZA984572B/en unknown
- 1998-05-28 ZA ZA984571A patent/ZA984571B/en unknown
- 1998-05-28 ZA ZA984573A patent/ZA984573B/en unknown
- 1998-05-28 KR KR10-1999-7011038A patent/KR100480360B1/en not_active IP Right Cessation
- 1998-05-28 CN CNA2008101005365A patent/CN101293869A/en active Pending
- 1998-05-28 UA UA99127139A patent/UA66362C2/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR100480360B1 (en) | 2005-04-06 |
KR20010013059A (en) | 2001-02-26 |
ZA984573B (en) | 1999-01-21 |
ZA984572B (en) | 1998-12-03 |
UA66362C2 (en) | 2004-05-17 |
UA66361C2 (en) | 2004-05-17 |
CN101293869A (en) | 2008-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL133008A0 (en) | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | |
PL348605A1 (en) | Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors | |
PL348979A1 (en) | Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors | |
PL349032A1 (en) | Quinoline and quinoxaline compounds | |
HK1026209A1 (en) | Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors | |
PL331154A1 (en) | Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase | |
IL127796A0 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
HK1035188A1 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
HK1208456A1 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors 3- | |
IL137041A0 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
HU9602017D0 (en) | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor | |
IL145870A0 (en) | Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases | |
ZA984573B (en) | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases | |
AU2876000A (en) | Tyrosine kinase inhibitors and methods of using the same | |
HUP0002219A3 (en) | Quinoline and quinoxaline derivatives which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases and pharmaceutical compositions containing them | |
GB9600997D0 (en) | N-indolinyl-pyridopyrimidines as tyrosine kinase inhibitors | |
ZA9710727B (en) | Substituted pyrimidine compounds and methods of use. | |
ZA987649B (en) | Imidazoquinoxaline protein tyrosine kinase inhibitors. |